# EDGAR Filing Document

**Accession Number:** 0001795091
**File Stem:** 0001213900-26-037476
**Filing Date:** 2026-3
**Character Count:** 12249
**Document Hash:** 0f592ab2141996eb70b437c1b56877e1
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-26-037476.hdr.sgml**: 20260331

**ACCESSION NUMBER**: 0001213900-26-037476

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 14

**CONFORMED PERIOD OF REPORT**: 20260331

**ITEM INFORMATION**: Other Events

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20260331

**DATE AS OF CHANGE**: 20260331

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** OS Therapies Inc
- **CENTRAL INDEX KEY:** 0001795091
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 825118368
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-42195
- **FILM NUMBER:** 26822220

**BUSINESS ADDRESS:**
- **STREET 1:** 15825 SHADY GROVE ROAD
- **STREET 2:** SUITE 135
- **CITY:** ROCKVILLE
- **STATE:** MD
- **ZIP:** 20850
- **BUSINESS PHONE:** 410-297-7793

**MAIL ADDRESS:**
- **STREET 1:** 15825 SHADY GROVE ROAD
- **STREET 2:** SUITE 135
- **CITY:** ROCKVILLE
- **STATE:** MD
- **ZIP:** 20850

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** OS THERAPIES Inc
- **DATE OF NAME CHANGE:** 20191125

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, DC 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the**

**Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): <u>March 31, 2026</u>

**OS THERAPIES INCORPORATED**

(Exact name of registrant as specified in its charter)

<u>Delaware</u> <u>001-42195</u> <u>82-5118368</u> <br> (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.)

<u>115 Pullman Crossing Road, Suite 103 Grasonville, Maryland</u> <u>21638</u> <br> (Address of Principal Executive Offices) (Zip Code)

Registrant's telephone number, including area code: <u>(410)</u> 297-7793

N/A

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of Each Class** | **Trading Symbol(s)** | **Name of Each Exchange on Which Registered** |
| Common Stock, par value $0.001 per share | OSTX | NYSE American |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

**CURRENT REPORT ON FORM 8-K**

**OS Therapies Incorporated**

**March 31, 2026**

**Item 8.01. Other Events.**

On March 31, 2026, OS Therapies Incorporated (the "Company") filed with the U.S. Securities and Exchange Commission (the "SEC") a prospectus supplement (the "Prospectus Supplement"), which forms a part of the Company's registration statement on Form S-3 (File No. 333-289443), which was previously filed with the SEC on August 8, 2025 and declared effective on August 12, 2025. The Prospectus Supplement covers the resale from time to time of up to 10,529,417 shares of the Company's common stock (the "Shares") by the selling stockholders referenced in the Prospectus Supplement. The Company is filing this Current Report on Form 8-K to provide the legal opinion of its counsel, Olshan Frome Wolosky LLP, regarding the legality of Shares, which is attached hereto as Exhibit 5.1.

**Item 9.01 Financial Statements and Exhibits.**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*(d) Exhibits.*

 

---

| | |
|:---|:---|
| **Exhibit<br> Number** | **Description** |
| 5.1 | [Opinion of Olshan Frome Wolosky LLP.](ea028392401ex5-1.htm) |
| 23.1 | [Consent of Olshan Frome Wolosky LLP (included in its opinion filed as Exhibit 5.1).](ea028392401ex5-1.htm) |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). |

---

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | | |
|:---|:---|:---|:---|
|  | **OS THERAPIES INCORPORATED** | **OS THERAPIES INCORPORATED** | **OS THERAPIES INCORPORATED** |
| Dated: March 31, 2026 | By: | /s/ Paul A. Romness, MPH | /s/ Paul A. Romness, MPH |
|  |  | Name: | Paul A. Romness, MPH |
|  |  | Title: | President and Chief Executive Officer |

---

## Exhibit 5.1

**Exhibit 5.1**

![](ea028392401_ex5-1img1.jpg)

March 31, 2026

OS Therapies Incorporated<br> 115 Pullman Crossing Road, Suite #103

Grasonville, Maryland 21638

Ladies and Gentlemen:

We are acting as counsel to OS Therapies Incorporated, a Delaware corporation (the "Company"), in connection with the prospectus supplement dated March 31, 2026 (the "Prospectus Supplement") constituting a part of the Registration Statement on Form S-3 initially filed by the Company with the Securities and Exchange Commission (the "Commission") under the Securities Act of 1933, as amended (the "Act"), on August 8, 2025 (as it may be amended, the "Registration Statement"), which became effective on August 12, 2025, relating to the offer and resale from time to time by the selling stockholders identified in the Prospectus Supplement of up to 10,529,417 shares of the Company's common stock, par value $0.001 per share (the "Common Stock"), consisting of (i) 4,289,441 shares of Common Stock (the "Warrant Shares") issuable upon exercise of certain of the Company's outstanding warrants (the "Warrants") and (ii) 6,239,976 shares of Common Stock (the "Conversion Shares") issuable upon conversion of the Company's outstanding unsecured convertible promissory notes (the "Notes").

We advise you that we have examined executed originals or copies certified or otherwise identified to our satisfaction of the following documents: (a) the Registration Statement, (b) the Prospectus Supplement, (c) the Warrants, (d) the Notes, (e) the Company's Third Amended and Restated Certificate of Incorporation, as amended to date, (f) the Company's Amended and Restated Bylaws, as amended to date, and (g) certain resolutions adopted by the Board of Directors of the Company. In addition, we have examined and relied upon such corporate records and other documents, instruments and certificates of officers and representatives of the Company and of public officials, and we have made such examination of law, as we have deemed necessary or appropriate for purposes of the opinions expressed below. As to certain factual matters, unless otherwise indicated, we have relied, to the extent we have deemed proper, on certificates of certain officers of the Company.

We have assumed for purposes of rendering the opinions set forth herein, without any verification by us:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) the genuineness of all signatures, the legal capacity of all
natural persons to execute and deliver documents, the authenticity and completeness of documents submitted to us as originals and the
completeness and conformity with authentic original documents of all documents submitted to us as copies, that all documents, books and
records made available to us by the Company are accurate and complete;

![](ea028392401_ex5-1img2.jpg)

March 31, 2026

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) that each Note has been duly authorized, executed and delivered by each party thereto, that each such
party is duly organized, validly existing and in good standing under the laws of its jurisdiction of organization and all jurisdictions
where it is conducting business or otherwise required to be so qualified, that each such party has full power, authority and legal right
to enter into and perform the terms and conditions of such Note to be performed by it, that the representations and warranties of each
such party as set forth in such Note when made were, and on the date hereof are, true and complete, and that such Note constitutes a legal,
valid and binding obligation of each such party, enforceable against it in accordance with their respective terms and that the Company
received the requisite approval from the NYSE American to list the Conversion Shares; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) that each Warrant has been duly authorized, executed and delivered by each party thereto, that each such
party is duly organized, validly existing and in good standing under the laws of its jurisdiction of organization and all jurisdictions
where it is conducting business or otherwise required to be so qualified, that each such party has full power, authority and legal right
to enter into and perform the terms and conditions of such Warrant to be performed by it, that the representations and warranties of each
such party as set forth in such Warrant when made were, and on the date hereof are, true and complete, and that such Warrant constitutes
a legal, valid and binding obligation of each such party, enforceable against it in accordance with their respective terms and that the
Company received the requisite approval from the NYSE American to list the Warrant Shares.

Based upon the foregoing and subject to the qualifications, assumptions and limitations contained herein, we are of the opinion that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. The Warrant Shares have been duly authorized and, when issued, delivered and paid for upon valid exercise
in accordance with the terms of the applicable Warrant, will be validly issued, fully paid and nonassessable.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. The Conversion Shares have been duly authorized and, when issued and delivered upon valid conversion in
accordance with the terms of the applicable Note, will be validly issued, fully paid and nonassessable.

We are members of the Bar of the State of New York. We do not express any opinion as to the effect of any laws other than the laws of the State of New York and the General Corporation Law of the State of Delaware, and the federal laws of the United States of America, as in effect on the date hereof.

This opinion letter is limited to the matters set forth herein, and no opinion may be inferred or implied beyond the matters expressly set forth herein. This opinion letter is not a guaranty nor may one be inferred or implied. This opinion letter speaks as of the date hereof and we assume no obligation to update or supplement this opinion letter to reflect any facts or circumstances that may hereafter come to our attention or any changes in fact or law that may hereafter occur.

We hereby consent to the filing of this opinion in accordance with the requirements of Item 601(b)(5) of Regulation S-K promulgated under the Act with the Commission as an exhibit to the Current Report on Form 8-K filed by the Company with the Commission on the date hereof and to the reference made to this firm under the caption "Legal Matters" in the Prospectus Supplement. In giving such consent, we do not hereby admit that we are in the category of persons whose consent is required under Section 7 of the Act or the rules and regulations of the Commission.

---

| |
|:---|
| Very truly yours, |
| */s/ Olshan Frome Wolosky LLP* |
| OLSHAN FROME WOLOSKY LLP |

---